eBytes: Rheumatoid Arthritis 1 - Epidemiology & Pathophysiology



Start Date:


End Date:




Max Credits:


Credit Type:



Program Information

Increase your rheumatology knowledge through ARHP Rheumatology eBytes intermediate learning level activities.


eBytes: Rheumatoid Arthritis 1 - Epidemiology & Pathophysiology provides core education for best practices regarding the pathophysiology and diagnostic considerations for up-to-date treatment options in less than 30 minutes. Use any mobile device or computer to listen at your convenience in between seeing patients or during your commute to work.


Includes the following:

  • Pre assessment
  • Video presentation
  • Post assessment and activity evaluation
  • AMA PRA Category 1 CreditsTM with a passing score of 70% or higher


Target Audience
The target audience is physicians, fellows-in-training, nurse practitioners, and physician assistants who care for those with rheumatic disease. Additionally, nurses, practice managers, physical therapists, occupational therapists, and medical and health professional students involved in the care of patients with rheumatic disease will benefit.


Learning Objectives
Upon completion of this online enduring activity, the successful learner will be able to:

  • Identify and discuss appropriate epidemiology and pathophysiology as related to the rheumatoid arthritis (RA) disease process.


Free for ACR/ARHP members - register online


Registration Fees

Free for ACR/ARHP members - online registration required. Not a member, join today. ARHP membership ranges from $30 - $140.

  • Member: $0
  • Non-Member: $50

CME Information

Accreditation Statement
The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement
The American College of Rheumatology designates this enduring online activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Health Professionals
Participants may claim credit and receive a Certificate of Participation for this activity.

Needs Assessment
In the United States, there are over 50 million adults and close to 300,000 children with arthritis 1, 2 and other rheumatic diseases. Often, because of lack of recognition of the signs and symptoms of these conditions, diagnosis and appropriate treatment is delayed 3-6. Rheumatic diseases are more frequently the cause of activity limitation than heart disease, cancer or diabetes. Forty percent of Americans have arthritis-related work limitations with an alarming rate of 60% reporting complete (100%) work disability after ten years of a Rheumatoid Arthritis (RA) diagnosis alone 1. With the current and expected workforce shortages, it is essential to provide pertinent and up to date education for physicians, health professionals, medical and health professional students and other clinicians regarding rheumatic diseases so that diagnosis and treatment occur early for best patient outcomes 7.  Because of the complexity of rheumatic conditions, including osteoarthritis and rheumatoid arthritis, there is a need to provide education that is applicable to non-rheumatology providers as well as those who are new to rheumatology 8.

ARHP is seeking to meet the various learning levels through online education activities geared towards learners on basic, intermediate and advanced levels. Rheumatology eBytes will offer intermediate opportunities which will meet a need of the members based on multiple survey responses.

References and Resources

  1. Rheumatic Diseases in America the Problem. The Impact. The Answer
  2. Helmick CG, Felson DT, Lawrence RC. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis & Rheum. 2008; 58(1):15-25.
  3. Yazdany J, MacLean CH. Quality of care in the rheumatic diseases: current status and future directions. Curr Opin Rheumatol 2008; 20: 159–66.
  4. Jacobi CE, Boshuizen HC, Rupp I, Dinant HJ, van den Bos GA. Quality of rheumatoid arthritis care: the patient's perspective. Int J Qual Health Care 2004; 16: 73–81.
  5. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000; 284: 984–92.
  6. Ganz DA, Chang JT, Roth CP, Guan M, Kamberg CJ, Niu F, et al. Quality of osteoarthritis care for community-dwelling older adults. Arthritis Rheum 2006; 55: 241–7.
  7. Deal CL, Hooker R, Harrington T, Birnbaum N, Hogan P, Bouchery E, et al. The United States rheumatology workforce: supply and demand, 2005–2025. Arthritis Rheum 2007; 56:722–9.
  8. Hooker RS. The extension of rheumatology services with physician assistants and nurse practitioners. Best Pract Res Clin Rheumatol 2008; 22:523–33.

Faculty and Disclosures

Scientific Editor - Benjamin J. Smith, PA-C, DFAAPA
Principal Faculty, Academic Coordinator, Teaching I
Florida State University College of Medicine, School of Physician Assistant Practice
Tallahassee, Florida

Author – Barbara A. Slusher, PA-C
Physician Assistant
University of Texas Medical Branch, Physician Assistant Studies
Galveston, Texas

CME Content Reviewers
The content of this activity was independently peer reviewed.
• Kori A. Dewing, DNP, ARNP, Seattle, Washington
• Atul A. Deodhar, MD, MRCP, Portland, Oregon

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Faculty participating in an ACR-sponsored activity must disclose to the editorial team and audience any financial or other relationship(s) including, but not limited to: 

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

Faculty disclosures listed apply in numeric format according to the list above. In accordance with ACR policy an individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for the development, management, presentation or evaluation of the CME activity.

Scientific Editor
Benjamin J. Smith, PA-C, DFAAPA - American Board of Internal Medicine, Rheumatology Board, honorarium for Board service, American Academy of Physician Assistants Commission on Continuing Professional Development and Education, Chair, non-compensated, Conference speaker-AAPA, GAPA, AANP 9

Barbara A. Slusher, PA-C - No relevant financial relationship to disclose


  • Kori A. Dewing, DNP, ARNP - No relevant financial relationships to disclose
  • Atul A. Deodhar, MD, MRCP - Glaxo Smith Klein-OHSU/Belimumab in ANCA Associated Vasculitis; Amgen-OHSU/Broadalumab in Psoriatic Arthritis; Pfizer-OHSU/Tofacitinib in Ankylosing Spondylitis; Novartis-OHSU/Secukinumab in Psoriatic Arthritis & Ankylosing Spondylitis; Eli Lilly-OHSU/Ixekizumab in Psoriatic Arthritis 2; AbbVie, Amgen, Beohringer Ingelheim, Janssen, Novartis, Pfizer, Sun Pharma, UCB, Advisory Boards; Spartan, Chair 9

*The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

This continuing medical education activity will not include reference(s) to unlabeled or unapproved uses of drugs or devices.

Corporate Support

Educational grant support for ARHP Rheumatology eBytes provided by Lilly USA, LLC, Celgene Corporation, and Mallinckrodt Pharmaceuticals.